BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors

Garrett W. Rhyasen, Yi Yao, Jingwen Zhang, Austin Dulak, Lillian Castriotta, Kelly Jacques, Wei Zhao, Farzin Gharahdaghi, Maureen M. Hattersley, Paul D. Lyne, Edwin Clark, Michael Zinda, Stephen E. Fawell, Gordon Mills, Huawei Chen

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

BRD4 is a transcriptional co-activator functioning to recruit regulatory complexes to acetylated chromatin. A subset of High-grade Serous Ovarian Cancer (HGSOC) patients are typified by focal, recurrent BRD4 gene amplifications. Despite previously described cancer dependencies, it is unclear whether BRD4 amplification events are oncogenic in HGSOC. We find that physiologically relevant levels of expression of BRD4 isoforms in non-transformed ovarian cells result in cellular transformation. Transcriptional profiling of BRD4-trans-formed ovarian cells, and BRD4-amplified HGSOC patient samples revealed shared expression patterns, including enriched MYC, and E2F1 gene signatures. Furthermore, we demonstrate that a novel BET inhibitor, AZD5153, is highly active in BRD4-amplified patient derived xenografts and uncover Neuregulin-1 as a novel BRD4 effector. Experiments involving Neuregulin-1 inhibition and exogenous addition, demonstrate Neuregulin-1 as necessary and sufficient for BRD4-mediated transformation. This study demonstrates the oncogenic potential of BRD4 amplification in cancer and establishes BRD4-amplified HGSOC as a potential patient population that could benefit from BET inhibitors.

Original languageEnglish (US)
Article numbere0200826
JournalPLoS One
Volume13
Issue number7
DOIs
StatePublished - Jul 1 2018
Externally publishedYes

Fingerprint

Neuregulin-1
ovarian neoplasms
Gene expression
Ovarian Neoplasms
Amplification
Gene Expression
gene expression
gene amplification
Heterografts
neoplasms
Chromatin
Gene Amplification
Protein Isoforms
Genes
chromatin
Neoplasms
cells
Experiments
Population
genes

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors. / Rhyasen, Garrett W.; Yao, Yi; Zhang, Jingwen; Dulak, Austin; Castriotta, Lillian; Jacques, Kelly; Zhao, Wei; Gharahdaghi, Farzin; Hattersley, Maureen M.; Lyne, Paul D.; Clark, Edwin; Zinda, Michael; Fawell, Stephen E.; Mills, Gordon; Chen, Huawei.

In: PLoS One, Vol. 13, No. 7, e0200826, 01.07.2018.

Research output: Contribution to journalArticle

Rhyasen, GW, Yao, Y, Zhang, J, Dulak, A, Castriotta, L, Jacques, K, Zhao, W, Gharahdaghi, F, Hattersley, MM, Lyne, PD, Clark, E, Zinda, M, Fawell, SE, Mills, G & Chen, H 2018, 'BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors', PLoS One, vol. 13, no. 7, e0200826. https://doi.org/10.1371/journal.pone.0200826
Rhyasen, Garrett W. ; Yao, Yi ; Zhang, Jingwen ; Dulak, Austin ; Castriotta, Lillian ; Jacques, Kelly ; Zhao, Wei ; Gharahdaghi, Farzin ; Hattersley, Maureen M. ; Lyne, Paul D. ; Clark, Edwin ; Zinda, Michael ; Fawell, Stephen E. ; Mills, Gordon ; Chen, Huawei. / BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors. In: PLoS One. 2018 ; Vol. 13, No. 7.
@article{6f1089585b0a45a29340e4e95f1458ee,
title = "BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors",
abstract = "BRD4 is a transcriptional co-activator functioning to recruit regulatory complexes to acetylated chromatin. A subset of High-grade Serous Ovarian Cancer (HGSOC) patients are typified by focal, recurrent BRD4 gene amplifications. Despite previously described cancer dependencies, it is unclear whether BRD4 amplification events are oncogenic in HGSOC. We find that physiologically relevant levels of expression of BRD4 isoforms in non-transformed ovarian cells result in cellular transformation. Transcriptional profiling of BRD4-trans-formed ovarian cells, and BRD4-amplified HGSOC patient samples revealed shared expression patterns, including enriched MYC, and E2F1 gene signatures. Furthermore, we demonstrate that a novel BET inhibitor, AZD5153, is highly active in BRD4-amplified patient derived xenografts and uncover Neuregulin-1 as a novel BRD4 effector. Experiments involving Neuregulin-1 inhibition and exogenous addition, demonstrate Neuregulin-1 as necessary and sufficient for BRD4-mediated transformation. This study demonstrates the oncogenic potential of BRD4 amplification in cancer and establishes BRD4-amplified HGSOC as a potential patient population that could benefit from BET inhibitors.",
author = "Rhyasen, {Garrett W.} and Yi Yao and Jingwen Zhang and Austin Dulak and Lillian Castriotta and Kelly Jacques and Wei Zhao and Farzin Gharahdaghi and Hattersley, {Maureen M.} and Lyne, {Paul D.} and Edwin Clark and Michael Zinda and Fawell, {Stephen E.} and Gordon Mills and Huawei Chen",
year = "2018",
month = "7",
day = "1",
doi = "10.1371/journal.pone.0200826",
language = "English (US)",
volume = "13",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "7",

}

TY - JOUR

T1 - BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors

AU - Rhyasen, Garrett W.

AU - Yao, Yi

AU - Zhang, Jingwen

AU - Dulak, Austin

AU - Castriotta, Lillian

AU - Jacques, Kelly

AU - Zhao, Wei

AU - Gharahdaghi, Farzin

AU - Hattersley, Maureen M.

AU - Lyne, Paul D.

AU - Clark, Edwin

AU - Zinda, Michael

AU - Fawell, Stephen E.

AU - Mills, Gordon

AU - Chen, Huawei

PY - 2018/7/1

Y1 - 2018/7/1

N2 - BRD4 is a transcriptional co-activator functioning to recruit regulatory complexes to acetylated chromatin. A subset of High-grade Serous Ovarian Cancer (HGSOC) patients are typified by focal, recurrent BRD4 gene amplifications. Despite previously described cancer dependencies, it is unclear whether BRD4 amplification events are oncogenic in HGSOC. We find that physiologically relevant levels of expression of BRD4 isoforms in non-transformed ovarian cells result in cellular transformation. Transcriptional profiling of BRD4-trans-formed ovarian cells, and BRD4-amplified HGSOC patient samples revealed shared expression patterns, including enriched MYC, and E2F1 gene signatures. Furthermore, we demonstrate that a novel BET inhibitor, AZD5153, is highly active in BRD4-amplified patient derived xenografts and uncover Neuregulin-1 as a novel BRD4 effector. Experiments involving Neuregulin-1 inhibition and exogenous addition, demonstrate Neuregulin-1 as necessary and sufficient for BRD4-mediated transformation. This study demonstrates the oncogenic potential of BRD4 amplification in cancer and establishes BRD4-amplified HGSOC as a potential patient population that could benefit from BET inhibitors.

AB - BRD4 is a transcriptional co-activator functioning to recruit regulatory complexes to acetylated chromatin. A subset of High-grade Serous Ovarian Cancer (HGSOC) patients are typified by focal, recurrent BRD4 gene amplifications. Despite previously described cancer dependencies, it is unclear whether BRD4 amplification events are oncogenic in HGSOC. We find that physiologically relevant levels of expression of BRD4 isoforms in non-transformed ovarian cells result in cellular transformation. Transcriptional profiling of BRD4-trans-formed ovarian cells, and BRD4-amplified HGSOC patient samples revealed shared expression patterns, including enriched MYC, and E2F1 gene signatures. Furthermore, we demonstrate that a novel BET inhibitor, AZD5153, is highly active in BRD4-amplified patient derived xenografts and uncover Neuregulin-1 as a novel BRD4 effector. Experiments involving Neuregulin-1 inhibition and exogenous addition, demonstrate Neuregulin-1 as necessary and sufficient for BRD4-mediated transformation. This study demonstrates the oncogenic potential of BRD4 amplification in cancer and establishes BRD4-amplified HGSOC as a potential patient population that could benefit from BET inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=85051756798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051756798&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0200826

DO - 10.1371/journal.pone.0200826

M3 - Article

VL - 13

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 7

M1 - e0200826

ER -